Skin grafting and tissue replacement for treating foot ulcers in people with diabetes

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Santema, Trientje B ^a   Poyck, Paul P C ^b   Ubbink, Dirk T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC FOOT; DIABETIC PATIENT; FOLLOW UP; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; INCIDENCE; LEG AMPUTATION; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SKIN GRAFT; SKIN TRANSPLANTATION; SYSTEMATIC REVIEW; TISSUE REPLACEMENT; TISSUE TRANSPLANTATION; ULCER HEALING; ADVERSE EFFECTS; AMPUTATION; FOOT ULCER; META ANALYSIS; PROCEDURES; STATISTICS AND NUMERICAL DATA; WOUND HEALING;

AMPUTATION; DIABETIC FOOT; FOOT ULCER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN TRANSPLANTATION; WOUND HEALING;

EID: 84970016865     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011255.pub2     Document Type: Review

References (81)

1. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. International Wound Journal 2006;3(3):181-7.
2. Caravaggi C, De Giglio R, Pritelli C, Sommaria M, Dalla Noce S, et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 2003;26(10):2853-9.
3. DiDomenico L, Emch KJ, Landsman AR, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds 2011;23(7):184-9.
4. Edmonds M, the European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. The International Journal of Lower Extremity Wounds 2009;8(1):11-8.
5. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19(4):350-4.
6. Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products. Journal of Wound Care 2015;23(3):149-56.
7. Landsman A, Roukis TS, DeFronzo DJ, Agnew P, Petranto RD, Suprenant M. Living cells or collegen matrix: which is more beneficial in the treatment of diabetic foot ulcers. Wounds 2008;20(5):111-6.
8. Lipkin S, Chaikof E, Isseroff Z, Silverstein P. Effectiveness of bilayered cellular matrix in healing of neuropathic diabetic foot ulcers. Wounds 2003;15(7):230-6.
9. Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Advances in Skin & Wound Care 2015;28:17-20.
10. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26(6):1701-5.
11. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcer. Artificial Organs 1997;21(11):1203-10.
12. Pollak RA, Edington H, Jensen JL, Kroeker RO, Gentzkow GD. A human dermal replacement for the treatment of diabetic foot ulcers. Wounds 1997;9:175-83.
13. Puttirutvong P. Meshed skin graft versus split thickness skin graft in diabetic ulcer coverage. Journal of the Medical Association of Thailand 2004;87(1):66-72.
14. Reyzelman A, Crews RT, Moore JC, Moore L, Mukker JS, Offutt S, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. International Wound Journal 2009;6(3):196-208.
15. Sanders L, Landsman AD, Landsman A, Keller N, Cook J, Hopson M. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Management 2014;60(8):26-38.
16. Uccioli L, Giurato L, Ruotolo V, Ciavarella A, Grimaldi MS, Piaggesi A, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. The International Journal of Lower Extremity Wounds 2011;10(2):80-5.
17. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24(2):290-5.
18. You HJ, Han SK, Lee, JW, Chang H. Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes--a pilot study. Wound Repair and Regeneration 2012;20(4):491-9.
19. You HJ, Han SK, Rhie JW. Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers. Journal of Wound Care 2014;23(11):521-30.
20. Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective, randomised comparative parallel study amniotic membrane wound graft in the management of diabetic foot ulcers. International Wound Journal 2013;10(5):502-7.
21. Hanft JR, Suprenant MS. Healing of chronic foot ulcer in diabetic patients treated with a human fibroblast-derived dermis. The Journal of Foot & Ankle Surgery 2002;41(5):291-9.
22. Moustafa M, Bullock AJ, Creagh FM, Heller S, Jeffcoate W, Game F, et al. Randomized, controlled, single-blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing diabetic ulcers. Regenerative medicine 2007;2(6):887-902.
23. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Advances in Skin & Wound Care 2005;18(5 Pt 1):258-66.
24. Pham HT, Rosenblum BI, Lyons TE, Giueini JM, Charzan JS, Habershaw GM, et al. Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. Wounds 1999;11(4):1044-6.
25. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatologic Surgery 2002;28:698-703.
26. NCT01693133. Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT01693133 (accessed 14 August 2015).
27. NCT02070835. Study of ReCell® Treating for Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT02070835 (accessed 14 August 2015).
28. NCT02120755. A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds. https://clinicaltrials.gov/ct2/show/NCT02120755 (accessed 14 August 2015).
29. NCT02331147. Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT02331147 (accessed 14 August 2015).
30. NCT02399826. Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT02399826 (accessed 14 August 2015).
31. Abbott CA, Garrow AP, Carrington AL, Morris J, Van Ross ER, Boulton AJ. Foot ulcer risk is lower in South Asian and African-Caribbean compared to European diabetic patients in the UK: the North-West Diabetes Footcare Study. Diabetes Care 2005;28(8):1869-75.
32. Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson U. Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot & Ankle International 1995;16(7):388-94.
33. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot?. Diabetes/Metabolism Research and Reviews 1999;16 Suppl 1:75-83.
34. Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005082.pub2]
35. Blozik E, Scherer M. Skin replacement therapies for diabetic foot ulcers: systematic review and meta-analysis. Diabetes Care 2008;41(4):693-4.
36. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews 2008;24 Suppl 1:3-6.
37. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006810.pub3]
38. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. The Lancet 2011;378(9785):31-40.
39. Dumville JC, O'Meara S, Deshpande S, Speak K. Alginate dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009110.pub3]
40. Dumville JC, Deshpande S, O'Meara S, Speak K. Foam dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009111.pub3]
41. Dumville JC, O'Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD009101.pub3]
42. Dumville JC, Deshpande S, O'Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD009099.pub3]
43. Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD003556.pub2]
44. Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Archives of Dermatology 1998;134:293-300.
45. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366(9498):1736-43.
46. Fernando ME, Seneviratne RM, Cunningham M, Lazzarini PA, Sangla KS, Mong Tang Y, et al. Intensive versus conventional glycaemic control for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010764]
47. Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Advances in Skin & Wound Care 2015;28(1):17-20.
48. Game F. Choosing life or limb. Improving survival in the multi-complex diabetic foot patient. Diabetes/Metabolism Research and Reviews 2012;28 Suppl 1:97-100.
49. Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products. Journal of Wound Care 2015;24(3):149-56.
50. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
51. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Lammer J, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes/Metabolism Research and Reviews 2012;28 Suppl 1:179-217.
54. Izumi Y, Satterfield K, Lee S, Harkless LB, Lavery LA. Mortality of first-time amputees in diabetics: a 10-year observation. Diabetes Research and Clinical Practice 2009;83:126-31.
55. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. The Lancet 2003;261:1545-51.
56. Jeffcoate WJ, van Houtum WH. Amputation as a marker of the quality of foot care in diabetes. Diabetologia 2004;47:2051-8.
57. Jull AB, Walker N, Deshpande S. Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD005083.pub3]
58. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD004123.pub3]
59. Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research 2009;9:115.
60. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Levin M. Prevention and treatment of diabetic foot ulcers. Journal of Wound Ostomy and Continence Nursing 1998;21:129-46.
62. Lewis J, Lipp A. Pressure-relieving interventions for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD002302.pub2]
63. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999;22:692-5.
64. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ 2009;339:2535.
65. Nabuurs-Franssen MH, Huijberts MS, Nieuwenhuijzen Kruseman AC, Willems J, Schaper NC. Health-related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia 2005;48(9):1906-10.
66. Pham HT, Rich J, Veves A. Wound healing in diabetic foot ulceration. A review and commentary. Wounds 2000;12(4):79-82.
67. Quattrini C, Jeziorska M, Boulton AJ, Malik RA. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 2008;31:140-5.
68. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
69. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews 2004;20 Suppl 1:S90-5.
70. Schultz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
71. Schunemann 2011a Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results, 'Summary of findings' tables. In: Higgins JPT. Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Schünemann HJ, Oxman AD, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results, drawing conclusions. In: Higgins JPT. Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
73. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed April 2014).
74. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217-28.
75. Skoutas D, Papanas N, Georgiadis GS, Zervas V, Manes C, Maltezos E, et al. Risk factors for ipsilateral reamputation in patients with diabetic foot lesions. The International Journal of Lower Extremity Wounds 2009;8:69-74.
76. Stockl K, Vanderplas A, Tafesse E, Chang E. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care 2004;27:2129-34.
77. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, van den Brink A, Koelemay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. European Journal of Vascular and Endovascular Surgery 2014;47(6):647-55.
78. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. British Journal of Pharmacology 2009;156:713-27.
79. Teng YJ, Li YP, Wang JW, Yang KH, Zhang YC, Wang YJ, et al. Bioengineered skin in diabetic foot ulcers. Diabetes, Obesity & Metabolism 2010;12(4):307-15.
80. Valensi P, Girod I, Baron F, Moreau-Defarges T, Guillon P. Quality of life and clinical correlates in patients with diabetic foot ulcers. Diabetes & Metabolism 2005;31:263-71.
81. Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD011255]